



Association of Imaging Producers & Equipment Suppliers
European Industrial Association for Nuclear Medicine and Molecular Healthcare

AIPES NEWSLETTER 2017



You did it again this year!

As the year draws to a close, we are delighted to report that it has been one of remarkable success. It is down to you: all of you who took part in the General Assembly, who led and contributed in the working groups, who are colleagues and friends of the AIPES community. Once again, you gave us your support, your confidence and your time.

It is an honour and a pleasure for us at the executive committee for the past 18 months to represent you all. We are proud to reflect your wishes, to give nuclear medicine the place it deserves in European healthcare, at the EU institution level, and to work together on behalf of patients. Halfway through our triennium, we are aware that our work would not be possible without your involvement. We look forward to continuing our mandate in the same spirit of partnership and co-operation.

Thank you all!



AIPES speaks at the OECD/NEA on molybdenum supply

AIPES continues to work closely with the Nuclear Energy Agency (NEA), a part of the OECD that supports the development of the safe, environmentally friendly and economical use of nuclear energy. The NEA has been involved since 2009 in co-ordinating global efforts to ensure a reliable and economically sustainable supply of molybdenum/technetium, having set up the High-Level Group on the security of supply of Medical Radioisotopes (HLG-MR) at a time of supply difficulties. AIPES is, of course, one of the key industry groups specialised in medical radioisotopes, working with experts from many countries and from supply chain members, and alongside the European Commission (Euratom) and the International Atomic Energy Agency (IAEA). In this capacity, we support the important activities of the HLG-MR.



AIPES plays a major role in supporting the HLG-MR through the activities of the AIPES Security of Supply (SOS) Working Group, in addition to attending HLG-MR meetings and contributing to important reports. The SOS Working Group guides the whole industry on short-to-medium-term medical isotope supply status, as well as issuing reports at HLG-MR meetings and co-ordinating the industry response to any supply challenges. This AIPES work complements the NEA reports on the medium-to-longer-term market demand and the likely future global capacity of the supply chain.



There were important changes in the supply chain in 2017, notably with the industry's switch from high-enriched uranium targets to low-enriched uranium targets. This important conversion - combined with some technical challenges in the supply chain - brought the NEA and AIPES together to ensure clear communications with both government and industry stakeholders about ongoing security of supply.

AIPES and the HLG-MR continue to work together on other important topics, including supporting the EU sponsored research projects (e.g. SAMIRA and SMER) set up in 2016 through co-operative work and joint presentations to the EC. This important work will continue through 2018.

Hester Larkin leaves NMAWG after seven years, Philippe van Put arrives

The 2017 European Association of Nuclear Medicine (EANM) Congress in Vienna in October hailed Hester Larkin as she stepped down after seven years leading the AIPES Nuclear Medicine Awareness Working Group (NMAWG). “It was a real challenge for our industry to carry nuclear medicine information messages to the general public. In 2010, Hester believed in it and our working group is now a must,” said AIPES Honorary President Guy Turquet de Beauregard.




The NMAWG is active on many fronts, from raising awareness on social networks to sending products to the nuclear medicine departments in hospitals around the world. It has undoubtedly exceeded its initial objective of bringing nuclear medicine closer to the general public and informing them of its real benefits.

Although Hester has departed, her initiatives and her sense of communication will remain the basis of our future work. “NMAWG is a real team success,” Hester said. “All of us on the working group were able to develop some innovative initiatives and provide relevant, much needed information for patients and key stakeholders. I am very proud of what we all have developed so far. Being Chair has been a real privilege for me and I know under the Chairmanship of Philippe van Put, the Working Group will go from strength to strength.”


Philippe van Put admitted that it was “a difficult succession” as he took on the leadership of the group. “Hester has shown great foresight in selecting her goals. She has established privileged links with different patient associations. It is an honour for me to follow her example and continue our projects for the benefit of the patient. Please join me in thanking Hester and wishing her the best of success in her future projects.” he said.

Going forward...

There was a such a strong and warm response to our fun, animated clips for the general public on the applications of nuclear medicine that we decided to continue our initiative. Our latest clip on the use of nuclear medicine to diagnose heart disease is out now, entitled, “*What is a nuclear cardiology scan? Diagnosis & prognosis of cardiac ischemia*”



www.whatisnuclearmedicine.com



Goodbye Reactor and Isotope WG, hello Security of Supply WG

The Reactor and Isotopes Working Group was one of the first groups created by AIPES. It was named at a time when exchanges were exclusively between partners in the nuclear medicine industry and research reactors. But it has become more important and visible over time, with actions carried out at European and global levels. As we move to a more patient-centred vision, it is time to change its title to better reflect its activities.



On July 11, 2017, the AIPES Executive Committee renamed the Reactor and Isotope Working Group (RIWG): it is now the Security of Supply Working Group (SoS WG). The new name more accurately reflects the objectives of this important working group, which is to assist international stakeholders in providing a secure, stable, and reliable supply of medical radioisotopes to meet patient needs.

The SoS WG (and predecessor RIWG) have focused on ensuring a reliable supply of Mo-99. It works with Mo-99 processors, research reactor operators, and Tc-99m generator manufacturers to make sufficient reactor capacity available for target irradiation throughout the course of the year to meet daily patient demand for Mo-99 and Tc-99m procedures. The SoS WG will strengthen its efforts to bring the requirements for other reactor-produced radioisotopes into its reactor scheduling coordination activities.

The Innovation Group under the spotlights


This year, the Innovation Working Group surprised us with its brilliant reports on the advances of nuclear medicine through the Innovation Focus newsletter.



Sebastien Ballet, Co-chairman of the Innovation Working Group said that Innovation Focus will be the place for communities like patients, physicians and decision makers to discover or to re-visit the benefits of nuclear medicine. *“The first issues of Innovation Focus are dedicated to the success stories in nuclear medicine. Consensually, hybrid imaging can be considered one of the most successful in nuclear medicine history and can be considered one of the most famous ambassadors by diagnosing and treating hundreds of patients daily. We wish nuclear medicine and Innovation Focus a long life!”* he said


Where NM is & where NM goes

A new leaflet has been published as part of an AIPES-backed awareness campaign devoted to nuclear medicine. Entitled, ‘Where nuclear medicine is, and where nuclear medicine goes’, it is addressed mainly at patients but also at non-nuclear physicians, decision makers and investors.




The AIPES Innovation WG wanted not only to highlight the current situation and successes of nuclear medicine, but also to detail the technological evolution in both diagnosis and therapy. It has a special focus on the development of tracers and the importance of specific imaging tools. There are also broader explanations on what can be expected in the short term from technology improvements, growth of applications in therapy and the use of theranostics in personalized medicine.

The new FRM II reactor and its promises for the future



The EU Observatory group was invited to the Technical University of Munich in October 2017 by Professor Winfried Petry, Scientific Director of the new Forschungs-Neutronenquelle Heinz Maier-Leibnitz (FRM II, research reactor Munich II). All participants, including EU representatives and representatives from European Medicine Agency, enjoyed the presentation and the visit which showed new techniques, new working tools, and lots of promise for nuclear medicine.



AIPES in the Mile High City: SNMMI 2017 in Denver, Colorado



We are now regulars at the annual Congress of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), which was in Denver, Colorado this year. Our members and associate partners appreciate the privileged space that we give them to meet and discover our new projects. In Denver, our booth was again a popular meeting place, and we were able to raise our profile at the congress.




A presence at the “City of Dreams” EANM 2017 – Vienna, Austria

Vienna, the Austrian capital, is one of Europe’s crown jewels. But modern Vienna is more than just a place for history: the home city of Sigmund Freud is a city for business and international encounters. It is also the EANM’s headquarters, and the EANM congress in October was particularly well organized at the Vienna Convention Centre.



For the first time, AIPES received a space among the Industry exhibitors area at the EANM congress, where we could communicate with all our stakeholders and have fruitful contacts.



AIPES GET TOGETHER HOTEL SOFITEL

The AIPES evening get-together organized on the rooftop of the Sofitel Stephansdom hotel was a great success, with 90 participants at the event.

It was also an opportunity for the AIPES Executive Committee to meet the EANM Board of Directors, to help shape our future collaborative projects in 2018.



Welcoming New Members in 2017



Jubilant Draximage :

Well known as a global leader in the development, manufacturing and commercialisation of radiopharmaceuticals for diagnosis and treatment, Jubilant Draximage, through their European representation in UK, became our Member on September 1, 2017 with the unanimous support of our General Assembly.

“We are passionately dedicated to advancing quality, sustainability and value in support the entire nuclear medicine community and this is why we want to join AIPES, to exchange on subjects of common interests and to cooperate to insure the on-going success of molecular imaging”, said Eric Guilbert, Jubilant Draximage’s Director Commercial Operations Europe, Canada, Asia.

<http://www.draximage.com/>



Cardinal Health NPS :

Cardinal Health joined AIPES as an Associate Partner on October 1, 2017.

Cardinal Health Nuclear Pharmacy Services operates the largest U.S. network of radiopharmacies and F.D.A. registered manufacturing sites that prepare and dispense the most comprehensive portfolio of radiopharmaceuticals in the U.S. The company expressed its interest in joining AIPES to participate in the different working groups and contribute to the future development of nuclear medicine. The representative at our General Assembly is the President of Nuclear Pharmacy Services, Tiffany Oslon.

<http://www.cardinalhealth.com/>

More to come : THE 2018 AIPES SYMPOSIUM

Don't miss our next Symposium, on March 22, 2018 entitled 'Molecular Imaging Guided Cancer Management for European Citizens', which will take place at the historic Solvay Library in Brussels. We are organising the event with the European Parliament's Committees for Health and Industry.

www.aipessymposium.eu



SAVE THE DATE

**Molecular Imaging Guided Cancer Management
for European Citizens**



An AIPES (*) symposium
Thursday 22 March at 10:00 - The Solvay Library, Brussels

Novel cancer therapies are revolutionising patient management and offer improved outcomes, quality of life and hope for those affected by cancer and those around them. However, such therapies tend to be very expensive, and while effective for patients with specific genetic profiles of the disease, they have no effect on others with different genotypes.

This fact compromises their benefits versus mainstream approaches at population level, while imposing severe strains to health systems. Moreover, it increases the investment risk for the development of further novel treatment developments.

Molecular imaging is an accurate, safe and economic answer to these concerns. By utilising state-of-the-art technology, localisation of the disease and genetic suitability for a candidate therapy is possible. This enables individualised treatments, allowing health systems to offer the best possible solution to each citizen while simultaneously containing treatment costs.

Join us on 22 March 2018, where experts from academia, clinic and industry will discuss with the audience the matters above.

 aipessymposium.eu
info@aipessymposium.eu

(*) AIPES is the European Industrial Association for Nuclear Medicine and Molecular Healthcare. We provide a wide scope of services & partnerships on behalf of our members. We maintain close contacts with EU commission, politicians, the European Medicines Agency, academia & the media. We also have partnerships with key EU Patient associations & other professional bodies in the healthcare field.

Ready for a successful year 2018 !





Association of Imaging Producers & Equipment Suppliers
European Industrial Association for Nuclear Medicine and Molecular Healthcare

AIPES, eeig.
Avenue Louise 65 - 4th Floor
B 1050 Brussels

Tel: +32 2 535 89 45
Email: admin@aipes-eeig.org
<http://www.aipes-eeig.org>